With recent developments in cancer treatment, the prominent anti-tumor effects of ICPIs, such as anti-CTLA4 and anti-PD-1 antibodies, have been demonstrated worldwide [45,46,47]. The gene discussed is CTLA4; the disease is neoplasm.